Bharat Biotech's Covaxin gets nod for phase 3 clinical trials

Bharat Biotech's Covaxin gets nod for phase 3 clinical trials

The two-dose vaccine, called BNT162b2, has been tested on 35,000 people so far, with nearly 40,000 people enrolled in the trials program to date.

An AstraZeneca spokesman said the initial results "further build the body of evidence for the safety and immunogenicity" of its experimental vaccine.

The vaccine, developed by the University of Oxford, also triggers lower adverse responses among the elderly, British drug maker AstraZeneca Plc, which is helping manufacture the vaccine, said on Monday.

The AstraZeneca/Oxford vaccine is one of the most promising and advanced in the world to combat the global pandemic, which has now claimed the lives of 1.1 million people.

Older people are also high on the priority list because their risks of serious illness and death from the coronavirus - which has killed more than 225,000 people in the U.S. - are much higher.

According to Bloomberg, AstraZeneca said in an email statement: "It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher".

The US Trump administration will this week announce a plan to cover out-of-pocket costs of COVID-19 vaccines for millions of Americans who receive Medicare or Medicaid, Politico reported late on Monday, citing four people with knowledge of the plan.

Speaking to Hindustan Times, Prasad said, "The DCGI has asked us to change a few details in the protocol". "Serum Institute of India is in the process of completing phase 2B and 3 trials but they also have phase 3 trials ongoing in Brazil, South Africa and the USA", the Indian Council of Medical Research DG said.

"Although we're not developing the vaccines ourselves, it is a lot of work".

Congress in March sought to mandate free coronavirus vaccine coverage as part of a broader Covid-19 relief bill.

Today's results parallel data from tests in July that showed the vaccine generated "robust immune responses" in a group of healthy adults aged between 18 and 55, says Reuters.

It comes as Tánaiste Leo Varadkar revealed he and the Government were optimistic about the rollout of a vaccine early next year.

The findings come after the Food and Drug Administration allowed AstraZeneca on Friday to resume its vaccine trials in the USA after a participant reported a "severe adverse reaction" on September 6.

There has also been developments in the USA regarding a vaccine breakthrough.

Concerns have also been raised for when hospitals first receive vaccines for front-line staff.

Related Articles